11.26
price down icon12.17%   -1.56
after-market Handel nachbörslich: 11.19 -0.07 -0.62%
loading
Schlusskurs vom Vortag:
$12.82
Offen:
$12.71
24-Stunden-Volumen:
9.87M
Relative Volume:
0.79
Marktkapitalisierung:
$1.86B
Einnahmen:
$596.34M
Nettoeinkommen (Verlust:
$-87.84M
KGV:
-18.85
EPS:
-0.5975
Netto-Cashflow:
$-97.62M
1W Leistung:
-11.69%
1M Leistung:
+20.43%
6M Leistung:
+30.32%
1J Leistung:
+32.78%
1-Tages-Spanne:
Value
$11.11
$12.84
1-Wochen-Bereich:
Value
$11.11
$13.34
52-Wochen-Spanne:
Value
$6.20
$13.38

Novavax Inc Stock (NVAX) Company Profile

Name
Firmenname
Novavax Inc
Name
Telefon
240-268-2000
Name
Adresse
21 FIRSTFIELD RD, GAITHERSBURG, MD
Name
Mitarbeiter
749
Name
Twitter
@novavax
Name
Nächster Verdiensttermin
2026-11-05
Name
Neueste SEC-Einreichungen
Name
NVAX's Discussions on Twitter

Compare NVAX vs VRTX, MRNA, REGN, ARGX, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
NVAX icon
NVAX
Novavax Inc
11.26 1.86B 596.34M -87.84M -97.62M -0.5975
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Novavax Inc Stock (NVAX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2025-08-28 Fortgesetzt H.C. Wainwright Buy
2025-08-20 Herabstufung BofA Securities Neutral → Underperform
2025-06-17 Eingeleitet Citigroup Sell
2025-02-28 Eingeleitet BTIG Research Buy
2024-07-30 Herabstufung JP Morgan Neutral → Underweight
2024-05-10 Hochstufung BofA Securities Underperform → Neutral
2024-05-10 Hochstufung JP Morgan Underweight → Neutral
2023-08-09 Hochstufung B. Riley Securities Neutral → Buy
2023-04-20 Herabstufung TD Cowen Outperform → Market Perform
2023-03-01 Herabstufung B. Riley Securities Buy → Neutral
2023-01-09 Bestätigt B. Riley Securities Buy
2022-12-30 Bestätigt H.C. Wainwright Buy
2022-12-02 Eingeleitet Jefferies Hold
2022-09-22 Herabstufung JP Morgan Neutral → Underweight
2022-05-20 Eingeleitet BofA Securities Underperform
2022-02-23 Bestätigt B. Riley Securities Buy
2022-02-22 Fortgesetzt Jefferies Buy
2022-01-21 Eingeleitet Cowen Outperform
2021-05-12 Herabstufung JP Morgan Overweight → Neutral
2020-12-14 Eingeleitet Jefferies Buy
2020-08-06 Bestätigt H.C. Wainwright Buy
2020-08-05 Hochstufung JP Morgan Neutral → Overweight
2020-08-05 Herabstufung Ladenburg Thalmann Neutral → Sell
2020-07-16 Bestätigt H.C. Wainwright Buy
2020-07-08 Herabstufung Ladenburg Thalmann Buy → Neutral
2020-06-29 Bestätigt B. Riley FBR Buy
2020-06-29 Bestätigt H.C. Wainwright Buy
2020-06-05 Hochstufung JP Morgan Underweight → Neutral
2020-05-28 Bestätigt B. Riley FBR Buy
2020-05-12 Bestätigt H.C. Wainwright Buy
2020-04-30 Bestätigt H.C. Wainwright Buy
2019-11-27 Fortgesetzt B. Riley FBR Buy
2019-08-14 Bestätigt H.C. Wainwright Buy
2019-02-28 Herabstufung Piper Jaffray Overweight → Underweight
2018-12-18 Eingeleitet Ladenburg Thalmann Buy
2018-12-11 Eingeleitet Oppenheimer Outperform
2018-11-26 Hochstufung Piper Jaffray Neutral → Overweight
2018-09-21 Hochstufung JP Morgan Underweight → Overweight
2018-03-29 Hochstufung Seaport Global Securities Neutral → Buy
Alle ansehen

Novavax Inc Aktie (NVAX) Neueste Nachrichten

pulisher
Oct 15, 2026

Novavax, Inc. Stock 12‑Month Price Target Raised to $15, Implies 19% Upside - TradingView

Oct 15, 2026
pulisher
Oct 15, 2026

NVAX Maintained by Citigroup -- Price Target Raised to $8.00 - GuruFocus

Oct 15, 2026
pulisher
Oct 14, 2026

Lobbying Update: $120,000 of NOVAVAX INC lobbying was just disclosed - Quiver Quantitative

Oct 14, 2026
pulisher
Oct 13, 2026

Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 13, 2026
pulisher
Oct 13, 2026

Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Novavax, Inc. (NVAX) Options Chain - Yahoo! Finance Canada

Oct 13, 2026
pulisher
Oct 13, 2026

Novavax Inc (Coinbase Tokenized Stock) - CryptoRank

Oct 13, 2026
pulisher
Oct 13, 2026

Novavax, Inc.: Revenue and Earnings Analysts Forecasts Revisions | NVV1 | US6700024010 - marketscreener.com

Oct 13, 2026
pulisher
Oct 12, 2026

Novavax, Inc. (NVAX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 12, 2026
pulisher
Oct 10, 2026

Novavax Inc. Stock Rises 15.8%, Outperforms Peers - Webull

Oct 10, 2026
pulisher
Oct 09, 2026

Novavax Inc (Coinbase Tokenized Stock) Analytics - CryptoRank

Oct 09, 2026
pulisher
Oct 09, 2026

Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 09, 2026
pulisher
Oct 09, 2026

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies - Yahoo Finance

Oct 09, 2026
pulisher
Oct 09, 2026

NVAX Stock Grinds Higher As Traders Watch Volatile Rebound - Timothy Sykes

Oct 09, 2026
pulisher
Oct 09, 2026

Novavax, Inc. Stock 12‑Month Price Target Raised to $14.86, Implies 35% Upside - TradingView

Oct 09, 2026
pulisher
Oct 09, 2026

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 09, 2026

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Oct 09, 2026
pulisher
Oct 08, 2026

Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Oct 08, 2026
pulisher
Oct 08, 2026

Novavax: Sell The False Plague Breakout (NASDAQ:NVAX) - Seeking Alpha

Oct 08, 2026
pulisher
Oct 08, 2026

Novavax (NVAX) Stock Could Be Above Fair Value As Plague Fears Fade - Yahoo Finance

Oct 08, 2026
pulisher
Oct 08, 2026

Should Novavax’s Headline-Driven Volatility Around Russia Health Scare Require Action From NVAX Investors? - Yahoo Finance

Oct 08, 2026
pulisher
Oct 08, 2026

Novavax: Vaccine Maker Sees Momentum In 2026, But Growth Story Holds Fundamental Risks - Seeking Alpha

Oct 08, 2026
pulisher
Oct 08, 2026

Novavax Inc (Coinbase Tokenized Stock) Price | NVAXc Price Today, Live Chart, USD converter, Market Capitalization - CryptoRank

Oct 08, 2026
pulisher
Oct 07, 2026

Novavax Inc Tokenized Stock (Coinbase) price today, NVAXc to USD live price, marketcap and chart - CoinMarketCap

Oct 07, 2026
pulisher
Oct 07, 2026

Transcript: Novavax Q2 2026 Earnings Conference Call - Benzinga

Oct 07, 2026
pulisher
Oct 07, 2026

Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility - Yahoo Finance

Oct 07, 2026
pulisher
Oct 06, 2026

Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 06, 2026
pulisher
Oct 06, 2026

Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research

Oct 06, 2026
pulisher
Oct 06, 2026

Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance

Oct 06, 2026
pulisher
Oct 06, 2026

NVAX Stock Slides As Momentum Traders Refocus On Fundamentals - StocksToTrade

Oct 06, 2026
pulisher
Oct 06, 2026

Novavax Stock Falls Back: What's Going On? - Benzinga

Oct 06, 2026
pulisher
Oct 06, 2026

Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna and Pfizer Inch Higher - Yahoo Finance

Oct 06, 2026
pulisher
Oct 06, 2026

Novavax, Moderna cool as WHO downplays plague-related death in Russia - Seeking Alpha

Oct 06, 2026
pulisher
Oct 06, 2026

Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research

Oct 06, 2026
pulisher
Oct 06, 2026

Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Yahoo Finance

Oct 06, 2026
pulisher
Oct 06, 2026

Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety - Benzinga

Oct 06, 2026
pulisher
Oct 05, 2026

Novavax, Nvidia, MercadoLibre, Nu Holdings and PTC: Why These 5 Stocks Are on Investors' Radars Today - Benzinga

Oct 05, 2026
pulisher
Oct 05, 2026

NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test - Yahoo Finance

Oct 05, 2026
pulisher
Oct 05, 2026

Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 05, 2026
pulisher
Oct 05, 2026

Novavax Shorts on Edge as Russia Plague Fears Spread - Benzinga

Oct 05, 2026
pulisher
Oct 05, 2026

Novavax, Inc. (NVAX) options chain - Yahoo Finance UK

Oct 05, 2026
pulisher
Oct 04, 2026

Novavax, Inc. (NVV1.DE) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 04, 2026
pulisher
Oct 02, 2026

Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch

Oct 02, 2026
pulisher
Sep 28, 2026

Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 28, 2026
pulisher
Sep 28, 2026

Novavax (NVAX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance

Sep 28, 2026
pulisher
Sep 28, 2026

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Sep 28, 2026
pulisher
Sep 27, 2026

NVAX: Daily Falling Wedge Setup Eyeing $11.13 Ahead of Q3 for NASDAQ:NVAX by TaxpayerTrades - TradingView

Sep 27, 2026
pulisher
Sep 24, 2026

Enterprise value to EBIT forward of Novavax, Inc. – BX:NVV1 - tradingview.com

Sep 24, 2026
pulisher
Sep 23, 2026

Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Sep 23, 2026

Finanzdaten der Novavax Inc-Aktie (NVAX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Novavax Inc-Aktie (NVAX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Ruxandra Draghia Akli
Former Officer
May 07 '26
Proposed Sale
9.87
30,000
296,083
0
Newton Charles W.
Director
Apr 25 '26
Option Exercise
0.00
9,520
0
9,520
Shiver John W.
Director
Mar 10 '26
Option Exercise
0.00
7,947
0
7,947
Kelly James Patrick
EVP, CFO and Treasurer
Mar 07 '26
Option Exercise
0.00
12,223
0
136,503
Kelly James Patrick
EVP, CFO and Treasurer
Mar 03 '26
Option Exercise
0.00
43,167
0
145,130
Jacobs John C
President and CEO
Mar 03 '26
Option Exercise
0.00
150,167
0
264,130
O'Hara Elaine
EVP, Chief Strategy Officer
Mar 03 '26
Option Exercise
0.00
56,334
0
157,071
Casey Mark J
EVP, Chief Legal Officer
Mar 03 '26
Option Exercise
0.00
37,500
0
101,445
Draghia-Akli Ruxandra
EVP, Research & Development
Mar 03 '26
Option Exercise
0.00
26,667
0
34,876
Jacobs John C
President and CEO
Mar 01 '26
Option Exercise
0.00
83,333
0
264,130
$31.32
price down icon 3.09%
$17.65
price down icon 0.28%
$17.10
price down icon 3.88%
$25.03
price down icon 2.80%
$20.30
price down icon 6.19%
$16.47
price down icon 5.34%
Kapitalisierung:     |  Volumen (24h):